UCI-1

N/A

Report date: 2025/01/26 16:35:46

Base Information

Drug NameUCI-1

Drug Alias NameSARS-CoV-2 3CL protease inhibitor (University of California Irvine)Irvine Coronavirus Inhibitor-1(University of California)SARS-CoV-2 MPro inhibitor (University of California Irvine)UCI-1

ClassificationBiologics > Protein drugs > Recombinant polypeptide

Mechanisms of ActionSARS-CoV-2-3C-like-proteinase inhibitors

TargetsSARS-CoV-2-3C-like-proteinase

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesUniversity of California Irvine

China Registration ClassN/A

Develop Information

Active CompaniesUniversity of California Irvine

Inactive CompaniesN/A

Active IndicationsCoronavirus Disease 2019 (COVID-19)

Inactive IndicationsN/A

Other Information

ATC CodeN/A